Junichi Kurebayashi
Overview
Explore the profile of Junichi Kurebayashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
878
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kanomata N, Kurebayashi J, Koike Y, Yamaguchi R, Moriya T
BMC Cancer
. 2019 Jan;
19(1):76.
PMID: 30651076
Background: Invasive micropapillary carcinoma (IMPC) of the breast is characterized by its unique morphology and frequent nodal metastasis. However, the mechanism for development of this unique subtype has not been...
12.
Kanomata N, Kurebayashi J, Moriya T
Med Mol Morphol
. 2018 Oct;
52(2):106-113.
PMID: 30317526
The development of trastuzumab has significantly improved the prognosis of HER2-positive breast cancer. However, disease recurs in some patients with HER2-positive breast cancer. A new strategy for treating HER2-positive breast...
13.
Hazama Y, Nakai Y, Sugawara S, Nomura T, Matsumoto K, Matsumoto R, et al.
Gan To Kagaku Ryoho
. 2018 Jul;
45(5):847-850.
PMID: 30026449
A 33-year-old woman became aware of a right breast mass at her 28th week of pregnancy. From the biopsy results, we diagnosed her with right breast cancer. At her 33rd...
14.
Kurebayashi J, Kanomata N, Koike Y, Ohta Y, Saitoh W, Kishino E
Breast Cancer
. 2018 Jun;
25(6):759-767.
PMID: 29946869
Background: The hedgehog (Hh) signaling pathway plays important roles in cell proliferation, malignant progression, invasion and metastasis, and the expansion of cancer stem cells (CSCs). Comprehensive immunohistochemical (IHC) analyses have...
15.
Ohashi Y, Shiba E, Yamashita H, Kurebayashi J, Noguchi S, Iwase H, et al.
Support Care Cancer
. 2017 Oct;
26(3):933-945.
PMID: 29063390
Background: We conducted an open-label, randomized controlled trial evaluating the appropriate treatment duration of leuprorelin acetate 3-month depot, TAP-144-SR (3M), administered postsurgically every 3 months for 2 years versus 3...
16.
Kanomata N, Matsuura S, Nomura T, Kurebayashi J, Mori T, Kitawaki J, et al.
PLoS One
. 2017 Aug;
12(8):e0183202.
PMID: 28792531
[This corrects the article DOI: 10.1371/journal.pone.0177439.].
17.
Goto R, Uda A, Hiroi S, Iwasaki K, Takashima K, Kurebayashi J
J Med Econ
. 2017 Aug;
20(11):1163-1169.
PMID: 28782387
Aims: The aim in this study is to evaluate economic value for leuprorelin acetate 6-month depot compared with leuprorelin acetate 3-month depot in Japanese pre-menopausal breast cancer patients from a...
18.
Kanomata N, Matsuura S, Nomura T, Kurebayashi J, Mori T, Kitawaki J, et al.
PLoS One
. 2017 May;
12(5):e0177439.
PMID: 28489882
Aromatase inhibitors have been widely used for the endocrine treatment of estrogen-dependent breast cancer in postmenopausal patients. However, clinicopathological studies of aromatase have been limited due to unsatisfactory specificity and/or...
19.
Kurebayashi J, Koike Y, Ohta Y, Saitoh W, Yamashita T, Kanomata N, et al.
Cancer Sci
. 2017 Feb;
108(5):918-930.
PMID: 28211214
Estradiol (E2) increases not only the cell growth but also the cancer stem cell (CSC) proportion in estrogen receptor (ER)-positive breast cancer cells. It has been suggested that the non-canonical...
20.
Koike Y, Ohta Y, Saitoh W, Yamashita T, Kanomata N, Moriya T, et al.
Breast Cancer
. 2017 Feb;
24(5):683-693.
PMID: 28144905
Background: Triple-negative breast cancer (TNBC) exhibits biologically aggressive behavior and has a poor prognosis. Novel molecular targeting agents are needed to control TNBC. Recent studies revealed that the non-canonical hedgehog...